Insiders Made Right Decision To Sell As Janux Therapeutics Dips 11%
Insiders Made Right Decision To Sell As Janux Therapeutics Dips 11%
Insiders seem to have made the most of their holdings by selling US$1.3m worth of Janux Therapeutics, Inc. (NASDAQ:JANX) stock at an average sell price of US$45.94 during the past year. The company's market valuation decreased by US$366m after the stock price dropped 11% over the past week, but insiders were spared from painful losses.
在过去的一年中,业内人士似乎以45.94美元的平均卖出价出售了价值130万美元的Janux Therapeutics, Inc.(纳斯达克股票代码:JANX)股票,从而充分利用了所持股量。在过去一周股价下跌11%之后,该公司的市场估值下降了3.66亿美元,但内部人士幸免于惨重的损失。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
尽管我们绝不会建议投资者仅根据公司董事的所作所为做出决定,但我们认为完全忽视内幕交易是愚蠢的。
The Last 12 Months Of Insider Transactions At Janux Therapeutics
Janux Therapeutics 过去 12 个月的内幕交易
In the last twelve months, the biggest single sale by an insider was when the insider, Sanford Madigan, sold US$758k worth of shares at a price of US$46.37 per share. That means that even when the share price was below the current price of US$55.37, an insider wanted to cash in some shares. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was only 11% of Sanford Madigan's holding.
在过去的十二个月中,内部人士最大的一次出售是内部人士桑福德·马迪根以每股46.37美元的价格出售了价值75.8万美元的股票。这意味着,即使股价低于当前的55.37美元,内部人士也想套现一些股票。通常,当内部人士以低于当前价格的价格出售时,我们认为这令人沮丧,因为这表明他们对较低的估值感到满意。但是,尽管内幕销售有时令人沮丧,但这只是一个微弱的信号。我们注意到,最大的单笔出售仅占桑福德·马迪根持股的11%。
Insiders in Janux Therapeutics didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Janux Therapeutics的内部人士没有购买任何股票。你可以在下面看到过去 12 个月的内幕交易(公司和个人)的直观描述。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Insiders At Janux Therapeutics Have Sold Stock Recently
Janux Therapeutics的内部人士最近出售了股票
Over the last three months, we've seen significant insider selling at Janux Therapeutics. Specifically, insiders ditched US$1.3m worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.
在过去的三个月中,我们看到了Janux Therapeutics的大量内幕抛售。具体而言,内部人士在那段时间抛售了价值130万美元的股票,我们没有记录任何购买记录。总的来说,这使我们有点谨慎,但这并不是万能的。
Insider Ownership
内部所有权
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Janux Therapeutics insiders own 9.5% of the company, currently worth about US$273m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
对于普通股股东来说,值得检查一下公司内部人士持有多少股票。较高的内部所有权通常会使公司领导层更加关注股东的利益。Janux Therapeutics内部人士拥有该公司9.5%的股份,根据最近的股价,目前价值约2.73亿美元。我喜欢看到这种程度的内部所有权,因为它增加了管理层考虑股东最大利益的机会。
So What Does This Data Suggest About Janux Therapeutics Insiders?
那么,这些数据对Janux Therapeutics内部人士有什么启示呢?
Insiders sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For instance, we've identified 5 warning signs for Janux Therapeutics (2 are significant) you should be aware of.
内部人士最近出售了股票,但他们一直没有买入。而且,即使我们看看去年,我们也没有看到任何购买。尽管内部人士确实拥有该公司的大量股份(这很好),但我们对他们交易的分析并不能使我们对公司充满信心。虽然我们喜欢了解内部人士的所有权和交易情况,但在做出任何投资决策之前,我们一定要考虑股票面临的风险。例如,我们已经确定了你应该注意的Janux Therapeutics的5个警告信号(2个很重要)。
But note: Janux Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但请注意:Janux Therapeutics可能不是最值得购买的股票。因此,来看看这份投资回报率高、债务低的有趣公司的免费清单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。